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Background: The therapeutic benefits of ketamine have been demonstrated for a
variety of psychiatric disorders. However, the role of ketamine induced psychoactive
experiences in mediating the therapeutic effects is unclear. Despite the growing
quantitative research on the efficacy of ketamine treatment, very few studies examined
participant experiences of ketamine infusions in a treatment setting.
Aims: The current study aimed to examine participant experiences of ketamine infusions
and how these relate to therapeutic mechanisms in a clinical trial setting.
Methods: We conducted semi-structured interviews with 12 participants who received
up to three ketamine infusions (0.8 mg/kg) as part of a Phase II double blind, randomised
controlled trial. The interviews explored participants’ acute experiences of ketamine
infusions, experiences of psychotherapy/education, and the lasting effects of the trial.
The interviews were transcribed verbatim and analysed using thematic analysis.
Results: Six key themes were identified. (1) Participants reported multifaceted
motivations for trial participation. (2) The set and setting was found to be influential in
determining acute ketamine experiences. The acute ketamine experiences included: (3)
the inherent contradictions of the experience (e.g., dissociation vs feelings of connection),
(4) rapidly fluctuating and changing experiences, (5) meaningful, mystical and spiritual
experiences. Finally, the final theme (6) relates to the transformational effects of the
infusions and the trial.
Conclusion: Provided in a supportive and professional environment, ketamine treatment
led to a significant change in relationship with alcohol. Ketamine induced ego dissolution
and dissociation were reported to be related to the transformational effects on
relationship with alcohol. The extent to which the acute psychoactive effects of ketamine
mediate therapeutic effects on drinking outcomes remain to be investigated in the trial
data. The acute effects of ketamine reported by our participants transcend its traditional
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conceptualisation as a “dissociative anaesthetic”; therefore, we suggest the development
or use of new measures alongside ketamine infusions to fully capture the spectrum of
these effects which may be crucial in its therapeutic and transformative effects.
Keywords: alcohol use disorder, ketamine, psychedelics, dissociation, thematic analysis, qualitative study,
clinical trial
INTRODUCTION
Ketamine is an N-methyl-d-aspartate (NMDA) receptor
antagonist, which produces powerful dissociative effects.
Ketamine was initially developed in the 1960s as an anaesthetic
drug (1), but there has been a recent escalation in interest
for its use in treating psychiatric disorders. Ketamine has been
characterised as a “dissociative anaesthetic” due to strong sensory
dissociation associated with it (1) [for a review of terminology
referring to similar classes of drugs including “psychedelics,”
“hallucinogens,” “entheogens,” “psychotomimetics” see (2)].
At a sub-anaesthetic dose, ketamine has been shown to
display rapid antidepressant effects (3–5) and there is further
evidence demonstrating its therapeutic benefits for a variety
of psychiatric disorders such as unipolar/bipolar depression,
post-traumatic stress disorder, generalised anxiety disorders,
obsessive compulsive disorder, and substance use disorders
(6). A small number of studies demonstrate the therapeutic
effects of ketamine on drug abstinence, drug use, craving and
withdrawal [see (7) for a review], and most recently alcohol use
disorder (8, 9). Although the safety and efficacy of ketamine has
been well-established, few studies thus far have looked at the
phenomenological experiences of people who have been given
the drug therapeutically and how these relate to mechanisms of
therapeutic benefits (10, 11).
Ketamine acutely can induce mystical and psychedelic
effects [for a full review of mechanisms of action see (12)].
Whilst these have been thought of as adverse effects in the
psychiatric literature, there is evidence to suggest that these
effects may be important therapeutically. In an early study
of Ketamine Psychedelic Therapy in patients with alcohol use
disorders, negative experiences during the ketamine session
(i.e., experiences associated with fear, anxiety, horror, and other
negative emotions) were positively correlated with the length
of remission (13). In a subsequent study where participants
with heroin use disorders were randomised to receive either a
“psychedelic” dose of ketamine [2.0 mg/kg Intramuscular (IM)]
or a “sub-psychedelic” dose (0.2 mg/kg IM), the rate of abstinence
over 2 years was higher in the former group than the latter (14)
indicating a therapeutic benefit of ketamine-induced psychedelic
experiences. Additionally, in a recent report antidepressant
response was correlated with dimensions of altered states of
consciousness such as feelings of unity, spirituality and insight
(15). Moreover, ketamine’s therapeutic effects on motivation
to quit cocaine and cocaine use were mediated by ketamine’s
mystical type effects—but not dissociative effects (16, 17).
Whilst some studies (18, 19) have described the experiences
during treatment, there have been no qualitative studies of
the experiences of participants during ketamine treatment for
alcohol use disorders, and as far as we are aware of only a handful
of studies that have looked at ketamine experiences qualitatively
in any treatment setting (10, 11).
The participants in the present study were a subsample of
participants from a recently completed randomised controlled
trial, Ketamine for the Reduction of Alcoholic Relapse (KARE),
which investigated ketamine as a treatment for alcohol use
disorders (8). In this trial, three infusions of ketamine, compared
to matched placebo, were found to be effective at prolonging
abstinence from alcohol in recently detoxified patients with
alcohol dependence, with the greatest benefit at 6 months
observed in those who had also received psychological therapy.
Whilst quantitative data are useful for establishing efficacy of
novel treatments, qualitative data about patient experiences may
provide insight into potential mechanisms of such treatments,
particularly in newly developing fields such as psychedelic
treatment. Additionally, qualitative data can provide important
additional information alongside psychometric measures from
clinical trials such as motivations and experiences of ketamine
treatment which can inform the design of future trials. In
the current study, we investigated the retrospective subjective
experiences of participants who received at least one ketamine
infusion and psychotherapy/psychoeducation as part of this
clinical trial. Through semi-structured interviews we aimed to
explore participants’ acute psychological experiences under the
ketamine infusions and perceived long-term effects of ketamine
treatment and the overall trial.
MATERIALS AND METHODS
Design
The current study involved semi-structured interviews which
lasted up to an hour and a half each and were conducted by
two members of the team (O.M.M., J.K.). Before commencing
the interview, participants were invited to guess which condition
they had been allocated to, as they had been blinded up to
this point. The interviews comprised of three main sections:
questions based on acute and subacute ketamine experiences,
experiences of rumination (reported elsewhere), and current
drinking levels (see Appendix for the interview schedule).
Participants were invited to elaborate on their experiences using
prompts and were invited to share any other experiences they
thought were particularly important.
Participants
Twelve participants (nine males and three females) who had
previously taken part in a Phase-II double blinded randomised
controlled multisite trial in London and South West England
were recruited in this follow-up study. The main inclusion
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criteria for the trial were being 18-60 years old, meeting
the Diagnostic and Statistical Manual of Mental Disorders
(DSM)-V criteria for severe alcohol use disorder or DSM-IV
criteria for severe alcohol dependence in the past 12 months,
currently abstinent from alcohol, and a negative urine drug
screen. Individuals on other relapse prevention medication
or antidepressants, those with uncontrolled hypertension, and
those with history of psychosis or first-degree family history of
psychosis were excluded [Full criteria are reported in McAndrew
et al. (8)].
Setting
The aim of the KARE trial was to assess the efficacy of
ketamine infusions combined with psychotherapy or alcohol
education on reducing relapse rates in recently detoxified alcohol
dependent individuals. In this trial, participants were given
ketamine (0.8 mg/kg) or saline placebo infusions weekly for 3
weeks alongside seven sessions of either psychological therapy
or alcohol education. The therapy or education sessions were
always timed immediately before the infusion and∼24 h after the
infusion. Prior to each infusion participants were read a script
to prepare them for the ketamine experience, which included a
suggestion to consider an intention for the session if they wanted
to. The infusion was administered by a blinded anaesthetist
through a cannula in the arm. During the infusion participants
reclined on a bed in a single room with dimmed lights,
listening to soothing music on headphones. Full instructions
provided to participants prior to their infusions can be found
in the Supplementary Materials. The infusion lasted 40min
and a psychologist and a nurse were present throughout the
infusion. Participants rated potential side effects before, during
and after the infusion on a standard scale developed for ketamine.
Participants were followed up at 3 and 6 months after the end
of treatment. Further details of the KARE trial are published
elsewhere (8). Out of 48 participants who had been allocated to
the ketamine group, only 25 were contactable. This is because
the consent forms outlining whether they had consented to
being contacted about future research were not accessible for all
participants at the time due to one of the clinical trial units being
closed during the COVID-19 Pandemic. These individuals were
invited to take part in this qualitative research and offered £30
reimbursement in online vouchers for their participation. Ethical
approval for this study was obtained from the Institutional
Ethics Committee at the University of Exeter (Reference no:
eCLESPsy001453 v7.1).
Procedure
Participants were contacted with an information sheet and
consent form for the study. Each participant was given a
participant ID and the data collected as part of the study was
stored separately from the consent forms. After giving informed
consent, participants who received at least one ketamine infusion
were invited to an online interview to gather data on their
acute experiences during the ketamine infusions. All interviews
were conducted online over Zoom, each interview was audio
recorded in its entirety and was transcribed verbatim by Zoom.
The recordings were checked by researchers for transcription
accuracy. Participants’ personal details were removed from the
transcripts to preserve anonymity and the audio recordings were
deleted once the interviews were transcribed and checked.
Data Analysis
The qualitative data were analysed with Reflexive Thematic
Analysis (TA). Reflexive Thematic Analysis as defined by Braun
and Clarke (20), seeks to identify patterns of meaning across a
dataset. It involves using qualitative methods of data collection
and analysis, within a qualitative paradigm (20, 21). It is
theoretically flexible and can be used in different frameworks to
answer different questions (20). We adopted a realist/essentialist
approach, whereby we assumed a straightforward relationship
between language and meaning. We initially sought to identify
participants’ experiences of ketamine at different stages of the
trial; pre-trial, acute experiences, and subacute experiences. Our
analysis was partly theoretical in that it was conducted within the
lens of current research on ketamine and its effects. However,
we endeavoured to stay as close as possible to the participants’
experiences and in doing so uncovered some effects of ketamine
previously not reported in other quantitative studies.
We followed the six stages of analysis identified and developed
by Braun and Clarke (20, 22). Two researchers reviewed the
transcripts numerous times to familiarise themselves with the
data. Initial codes were developed following a line by line reading
of the transcripts. After coding transcripts independently,
the researchers compared and discussed any discrepancies in
coding labels and conceptualisations of the codes. A consensus
was reached between the two researchers for each code,
disagreements between the two researchers were resolved by
discussion with a third researcher. Codes were then analysed
further to identify overarching themes underpinning the data and
develop a thematic model. Identifying themes was an iterative
and collaborative process involving the whole research team.
All researchers involved in the process considered how their
knowledge and experience might be impacting on the research
at all stages, as they wanted to stay close to the participants
experiences. Memos and research notes were kept to record this
process of reflection and this was a regular point of discussion in
researchmeetings. Literature on ketamine was partly drawn upon
to structure the analysis as we initially explore experiences before
trial participation, during acute and subacute effects of ketamine,
and the long term effects of ketamine and the trial.
RESULTS
Participant Characteristics
The demographic and clinical characteristics of the sample
who took part in the interviews are reported in Table 1. Ten
participants reported their age, which at the time of interview
ranged from 22 to 59 (M = 46.5, SD = 11.1). One participant
identified as Scottish Iranian, and the rest were White. The
time from last infusion to interview ranged from 11 months
to 3 years and 4 months. All participants except one were in
employment at the time of interviewing. Demographic details of
the full sample and results of psychometric measurements will
be available in the publication of the main trial data. Four of the
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twelve interviewed participants had received the psychotherapy
as part of the trial and the rest took part in alcohol education
sessions. All participants interviewed here correctly guessed their
allocation in the ketamine group.
At the time of enrolment in the KARE trial, participants had
met a mean of 7.7 (SD = 1.91) DSM-V criteria. Current DSM V
criteria were not measured at the time of interview, however we
recorded current drinking days per month and current craving
levels (see Table 1). Craving scores on the Alcohol Craving
Questionnaire Short Form—Revised ranged from 1.34 to 4.57 (M
= 2.91, SD= 0.82). Out of 12 participants interviewed here, three
were completely abstinent at the time of the interview and one
was abstinent except a recent binging episode. Following the trial,
length of abstinence ranged from nearly 2 weeks to 14 months
for those who were no longer abstinent, two participants had
completely remained abstinent since their participation in the
trial. Reasons for breaking abstinence following the trial included
mainly social events, stress and low mood, desire to drink and
celebrations. The rates of abstinence from alcohol use in the total
sample of the original KARE trial (N = 96) will be reported in
the publication of themain trial. The characteristics of the sample
interviewed closely resembled those of the total sample (N = 96).
Though a higher proportion of participants interviewed here had
received alcohol education compared to psychotherapy, which
was allocated on a 1:1 ratio in the trial.
Qualitative Results
Six key themes were identified following our thematic analysis
of all interviews, which explored participants’ experiences at all
stages of the trial (prior to the trial, acute experiences, subacute
experiences, and post-trial effects). These themes, which are
explored in detail below, include (See Table 2):
1. Multifaceted motivations for seeking ketamine in a
clinical trial.
2. Set and Setting as influential in determining acute
ketamine experiences.
3. The inherent contradictions of the acute ketamine experience.
4. Rapidly fluctuating and changing ketamine experiences.
5. Meaningful, spiritual and mystical experiences.
6. The ketamine infusions and the trial as
potentially transformative.
Multifaceted Motivations for Seeking Ketamine in a
Clinical Trial
Participants’ motivations to take part in the trial were often
multifaceted, with participants citing more than one reason
for their participation. The key motivations for participation
identified included: concern over their own alcohol use, hitting
rock bottom, altruism, legitimacy of the trial, and curiosity.
Motivations were both internally focused (e.g., participant’s
recognising their relationship with alcohol meant they needed
to take action to benefit their health) and externally influenced
(the legitimacy of the trial at a University and hospital
encouraged participation).
Concern Over Alcohol Use and Health
Participants were motivated to take part in the trial when they
assessed their own health as requiring action: “I was looking for
ways to just become a lot healthier. And to become just absolutely
teetotal” (P08). For the majority of participants, concerns over
alcohol use were a key motivator for taking part.
Hitting Rock Bottom
Some participants felt that their alcohol use was beginning to
“spiral out of control” (P12) and reported feelings of hopelessness
and suicidal thoughts related to their level of drinking, which led
them to engage with the trial. In this way the trial was described
as a “last chance”: “I was at my wit’s end, at my lowest point. I had
no escape, no way out of alcohol to the point of I knew if I carried
on, it would kill me” (P03).
Altruism
For some participants it was also the potential to help others
through taking part in this clinical research trial that provided
extra motivation for them to sign up: “My thought behind this
process was that if I did these 6 months and it helped others. That’s
something that I, I, you know, it’s a little bit of extra incentive for
me” (P05).
Legitimacy of the Trial and Curiosity
The legitimacy of the trial afforded by it being conducted at
a well-known University and a hospital, seemed to provide
reassurance for participants and sparked their curiosity
to participate:
“I sort of tend to be a little bit cautious with these sorts of things, but
because it was sort of university and hospital based, I thought well
you know, why not give it a go. The risks seem very small” (P02).
Indeed, many participants reported curiosity related to the
trial advertisement, noting in particular, interest in exploring
ketamine therapy as part of a clinical trial setting.
Set and Setting as Influential in Determining Acute
Ketamine Experiences
Set
Participants’ expectations of the infusions, elicited from past
experiences of changes in consciousness with and without drugs,
had an impact on their acute experiences of ketamine. Similarly,
the absence of prior drug experience exerted an influence on
participants’ acute experiences. For some participants who had
not used drugs recreationally in the past, the ketamine experience
was particularly novel. For one participant, speaking to a friend
who had used hallucinogenic substances prior to their second
infusion helped them to feel more “prepared” for the experience:
“And he advised me just to relax, he said, just chill out. Just have the
confidence that you’re gonna you’re going to get out of this. And the
whole situation will be more, will be better for you. And basically,
yeah that’s. I was prepared for it” (P04).
Participants’ prior mindset and spiritual beliefs were also
reported to affect their acute ketamine experience: “And for me,









































TABLE 1 | Demographic and clinical characteristics of participants.

































P02 59 Male White Exeter 4 3 7 Psychotherapy 20-25 2.74 39 days Social event No No 2 years and 8
months




N/A Yes Yes 1 year and 8
months
P04 53 Male White Exeter 7 3 7 Alcohol
education
8-10 2.58 40 days Desire to
drink
No Yes 1 year and 1
month




N/A No No 11 months
P06 56 Female White London 5 3 7 Alcohol
education
20 2.45 2 months Celebration Yes Yes 1 year and 8
months




3.55 6 months Stress and
low mood
Yes Yes 1 year and 1
month
P08 42 Male Scottish
Iranian
London 9 3 7 Alcohol
education
8 4.57 1-2 months Social event No Yes 2 years and 3
months
P09 35 Male White London 9 3 7 Psychotherapy 2 3.11 1 month Social event Yes Yes 1 year and 2
months






2.97 14 months Stress and
low mood
Yes Yes 1 year and 1
month
P11 50 Male White Exeter 10 3 7 Alcohol
education
14 2.58 12 days Social event No No 2 years and 6
months
P12 22 Male White Exeter 7 3 7 Alcohol
education
15-20 3.5 2 months Social event No No 2 years and 4
months
P13 48 Female White Exeter 7 1 2 Psychotherapy 28 1.34 Not known N/A Missing Missing 3 years and 4
months
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TABLE 2 | Themes, codes, example quotations.
1. Multifaceted motivations for seeking ketamine in a clinical trial
Concern over alcohol use and health “I was aware I was drinking too much, and it looked like a very interesting way of beginning to address it.” (P13)
Hitting rock bottom “...for me, it was kind of it felt like kind of like the last chance saloon really to kind of do something...” (P09)
Altruism “… I thought what if the ketamine trial proves successful and you know it just saves one life, someone who might die because of
alcohol dependency issues, and then it is worth my continuing.” (P04)
Legitimacy of the trial and curiosity “...I used to have a personal trainer and I noticed he posted on Facebook actually the KARE trial was happening. And that’s why I
saw about it and I just got intrigued by it.” (P11)
2. Set and Setting as influential in determining acute ketamine experiences
Set “... I’ve done that before with ketamine but in a gang of friends, which is kind of what you do with friends and it’s all a bit sloppy
and daft after a big techno night and it’s not something I’ve done much in the last five years before the trial anyway. But you
know, I do know that world and they’re lovely” (P06)
Setting “I had no idea what would happen... but then after that, the second and third I sort of went into the sessions with more intent to
explore and to get answers from certain things... it was nice to just do that and know that you’re in a safe environment and you
can come out the other side...It filled you with confidence and you know there’s no paranoia.” (P10)
3. Inherent contradictions of acute experience
Positive effects
A. Calmness and relaxation “It was peaceful. It was calming and I just sat back and... you know, I didn’t lose sense of who I was. I always knew who I was,
and I had confidence that this would be temporary.” (P04)
B. Reinforcing effects “I wanted this to carry on every week for the rest of my life. I wanted this experience in this, you know, sort of clinical place, I
would still be coming now you know what I mean?” (P05)
Negative experiences
A. Fear or panic “I knew where I was, but I just, it wasn’t a pleasant experience like the first one and then the end part, the second one. It was, it
was scary. And to the point of when you’re on it, you barely breathe, you’ve quite shallow breathing.” (P03)
B. Paranoid ideation “So it was a sort of mixture of extreme comfort for want of a better word with a sort of paranoia where one’s brain is saying, if you
guys in the room will leave the room, I’m stuck here for the rest of my life, sort of thing.” (P02)
C. Paralysis “It’s almost like a state of paralysis, where you do receive visual and sound information. But I don’t know how much sense I was
making to the people in the room around me. It feels like when you try and run in a dream, but your legs are move fast enough. In
fact, exactly like that.” (P08)
D. Nausea and vomiting “I was I didn’t feel particularly brilliant, to be honest. And then I started moving and just was aware I was going to be sick. And
then I was quite violently sick. So that was my experience.” (P13)




“… as far as I was concerned that was it. I was done. My human body wasn’t—I didn’t have a human body. I was something…
And even though I knew that I was kind of tethered, I didn’t know how I was going to get back to my body.” (P05)
Ego dissolution “The experience was genuinely remarkable in terms of the both the visual effects and…. the sort of removal of ego that
accompanied that. I felt that I was one with the whole universe and it sounds hippy dippy but that’s how I felt... I think I related to
this sort of ego changing, the size of the ego in me as well as a sort of physical sensation.” (P07)
Changes in experiences over time “So, the first one was very trippy and like going into another dimension. And then the second one, because I wanted to go into
that dimension, I think I was trying to go there and then I got a bit sort of like, oh, I can hear voices. This is putting me off... And
then the third one... I wasn’t well at all after that...As I said I couldn’t come around from it.” (P03)
4. Rapidly fluctuating and changing experiences
Perceptual distortions
A Visual distortions “I remember looking at the light above my head in the window and sort of blinking and as I blinked the of the colours changed.
Even though... the picture in my mind, the light in the window was the same.” (P07)
B Auditory distortions “...there were pieces that I was familiar with, but they were just, they were coming—It’s like different aspects that made up the
piece were coming through a different speeds or different pitches. They were just sounding like unique. … I could still hear them
as piano pieces but they weren’t the pieces that I knew.” (P04)
C Hallucinations or visions “I saw...this very strong vision of the synapse travelling across the neural pathway, then me typing into my phone, him getting the
message him talking to someone else, and like this chain of communication, essentially that got bigger and bigger and bigger and
bigger and bigger, to the point where it zoomed right out and you’re seeing the earth hanging there in space along with say 20,
25, 30 other inhabited planets all there in the cosmos.” (P09)
5. Meaningful, spiritual, and mystical experiences
Ego dissolution “It was a sense of completeness sense of, I suppose in a way finality, a source of finish. But also, a sense of enormous growth
and a feeling of oneness with other entities, other living beings in particular, but also the world and universe as a whole.” (P.07)
Epiphanies and Enlightenment “I think the first two like, they sort of left me… like they answered a lot of questions. You know, thinking about my children and I
have a stepdaughter and… It was things about that. And about, you know what I should be doing and how I should be, you
know, I don’t know it seemed to be like all the things that are really heavy on my mind and that I stress about whatever it was sort
of going through those things...just realising how little importance some things had or were...” (P10)
(Continued)
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TABLE 2 | Continued
Transcendence of time “...while we’re on the subject of time. I mean, that just goes bananas and I love it... It’s almost like... this afternoon, this evening,
the way we think of that—That just blows apart and doesn’t exist anymore.” (P06)
Hallucinations or visions “I was lying there, and there was this, there was this like a cacophony coming from the hallway, everyone was going like, like he’s
coming he’s coming! And I was like what’s going on, you know, like thinking this shouldn’t be happening in the hospital, I thought
this is a peaceful place and everyone’s like rushing out into the hallway to see what’s happening. And it’s this cartoon very simply
drawn constructed of neon light rendering of God, essentially is walking down the corridor...and he came up to me and he was
like...you can ask me two questions.” (P09)
6. The ketamine infusions and the trial as transformational
Perspective on life “It helped family wise, relationship wise in every, every single avenue of my life. It’s changed it...doing the ketamine and seeing this
other dimension enforced my belief of another life and I now live every single day to the max. When I go for a walk, I’m very
observant of my world around me. I take pleasures in life rather than pleasures of...drink...So...it’s still with me and I hope it’ll stay
with me for forever.” (P03)
Relationship with alcohol “I think before the trial all my life was sort of focused around alcohol. I was either drinking it at home or selling it to students or
working in an event where there was alcohol, the alcohol was a focus of it. So it was sort of everything and then afterwards, it just
sort of stopped...I enjoy a drink every now and then, but under much safer ways really...So it just made me realise I don’t need to
sort of drink to excess because there’s nothing else to do. I can just do other things...and that alcohol isn’t everything.” (P12)
Positive experiences of
psychotherapy and alcohol education
“You definitely need that support system. It feels like that you get with the therapy and the fact that you can take that home with
you as a crutch. So yeah, it was, it was very good, obviously painful in some parts, but you know I was at my most... desperate. I
wouldn’t be here now, if it wasn’t for it. I can definitely say that.” (P03)
Interaction of ketamine with psychotherapy or education
A. Ketamine interacting with
psychotherapy or education
“If I had just gone to education sessions and gone: ‘oh well I work around alcohol all day, I am pretty sure I know all the stuff I
need to know about it,’ I probably wouldn’t have listened so deeply. But the ketamine sort of made me more willing to engage
with it” (P12)
B. No impact of ketamine on
psychotherapy or education
“I don’t think there was any correlation there because the effects had fully worn off before we would go into that kind of
conversation.” (P08)
Ketamine and talking sessions as
mutually supportive
“I was kind of more open to understanding those mental and physiological impacts of alcohol because of the mental effects I’ve
had from the ketamine. Um, so I think there was there was a sort of mutually supportive relationship between both elements to
the therapy.” (P07)
Non-specific trial effects “It’s more the sort of holding hands that one needs, you need somebody who you’ve sort of divulged all your innermost secrets
to. Having done that, it then sort of makes you think twice about buying that bottle of wine. It’s that sort of attention that you get
that I think is valuable in this sort of thing.” (P02)
the idea that science and a form of spiritual practise or awareness
are two wings of the same bird. So, I think that probably informed
how I experienced this” (P09).
Participants’ experiences during the trial and expectations
following the first infusion also appeared to affect their
experiences of the following two infusions. For instance, one
participant recounted that concerns by the trial staff about their
mood following the first infusion led to a discussion on whether
they can continue with the infusions, and although they were able
to continue, this experience impacted their next infusions:
“The process of getting back on the trial and having to fight for it
meant that I was carrying some sort of negative feelings. And that’s
slightly obscured those positive aspects that I had before [during the
first infusion] . . . I was nervous and that affected the experienced I
had.” (P07).
Setting
The setting in which the trial took place was described as
“professional,” “controlled,” “carefully regulated,” and “clinical.”
As participants reported that the legitimacy of the trial was one of
the reasons that motivated their participation in the trial, related
to this they reported feeling safe and being comforted by the
professionalism of the trial staff as well as the clinical setting in
which the trial took place: “I thought it was amazing how clinical
it was and how organised it was and how safe I felt with it. That
was brilliant” (P11).
This professional and regulated setting of the trial was
reported to play an important role in determining participants’
acute ketamine experiences:
“I just thought, right ‘How extreme is this experience going to be?
Is it going to be a ride from hell or something like that?” And it
absolutely wasn’t and that’s down to the laboratory type conditions,
the controlled environment” (P08).
The Inherent Contradictions of the Acute Ketamine
Experience
The acute ketamine experiences of our participants were
characterised by inherent contradictions. Participants described
experiences that were both highly positive and negative and
could be conceptualised as a “rollercoaster ride.” It is also worth
noting the negative experiences were largely transient and that
despite these negative experiences, most participants described
their acute ketamine experience as overall pleasant: “I just found
I left every session, kind of, you know, feeling happy. Feeling, you
know. . . feeling lighter. . . Feeling like clearer thoughts” (P10).
This “rollercoaster” was experienced differently by each
participant and whereas for some, experiences were largely
positive, for others the rollercoaster led to a real divergence
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FIGURE 1 | Diagram depicting the relationship between set and setting, the acute ketamine experiences (inherent contradictions of the experience, rapidly fluctuating
and changing experiences, and meaningful, spiritual and mystical experiences) and transformative effects of the infusions and the trial. Whilst set and setting are
influential in determining the acute ketamine experiences, experiences from the first two infusions and the transformative effects also contribute to the set of the
subsequent infusions as expectations. As discussed in theme 4, the acute ketamine experiences, particularly feelings of connectedness and dissociation also
appeared to be related to the transformative effects.
of positive and negative effects, all occurring in the context
of differing/vivid psychedelic experiences, as we will discuss
further below.
Changes in Experiences Over Time
Moreover, exploring participants’ experiences across the
three infusions highlighted further contradictions—for some
participants the infusion experiences were qualitatively similar,
others described each infusion having a unique effect:
“The first one was in the imagination..., with what I know as a
human being, got my mind my will being put on it. . . . And the
second one was just freedom and just wow. . . . The third one was
a little bit too short, and as I came out I was panicky. I was just like
‘that’s it, we’re done”’ (P05).
Some participants perceived the experiences as less vivid/potent
as the trial progressed due to the reliability of the effects: “I think
having, having had it a couple of times, I was kind of probably more
used to what I was expecting. I suppose it was less of a wow, this is
amazing, because I’ve done it before” (P07).
This reduction in the strength of effects across the infusions
was reported to lead to dissatisfaction due to expectations from
previous infusions and a desire to replicate such experiences: “My
body was still starting to disappear, but not as quick so. It’s almost
like your body gets used to it” (P03).
Positive Experiences
As seen in Figure 1, positive effects identified during the
infusions included feelings of calmness and relaxation. Particular
experiences were feeling relieved, unhooked, mellowed, carefree,
chilled, and peaceful:
“It was, um, it was a sort of sense of complete relaxation, a sense
of sort of vanishing, you can, it feels like one was being sort of
enveloped in a duvet type, you know, that sort of feeling, if you like”
(P02).
Another positive aspect of the experience was the reinforcing
effects of ketamine. Participants described the experiences
associated with the ketamine infusions using terms such
as “beautiful,” “fantastic,” “brilliant,” and “amazing.” Several
participants reported the experience as “life changing” or “one
of the best experiences of my life.”
Due to the positive effects of ketamine infusions, feelings of
loss and sadness were described in relation to the cessation of the
ketamine infusion and the trial. Participants reported wanting the
experience to continue, or that they would benefit from a larger
number of sessions (e.g., six rather than three); this was related
to the changes in experiences across infusions which meant that
each infusion led to a deeper understanding:
“Because there’s the three sessions, really like I wanted to do six
thinking back on it because I felt like the third one, I just really
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cracked into something and you know to go a little bit further, I
think would have been really good” (P09).
Negative Experiences
On the other hand, the transient negative effects included fear
or panic, mild paranoid ideation, paralysis, and nausea and
vomiting. Nearly all participants experienced some form of
transient psychological or physical distress during the acute
ketamine infusion. Participants commonly described fear of
permanently losing their sense of self and body. This fear was
attributable to a sense that the trial would never end: “It was the
fear factor of I couldn’t get out of it. I couldn’t come off it” (P03).
Despite reports of feeling safe and comforted by the
professionalism of the trial staff, several participants started to
question the veracity of the trial and the motivations of the trial
staff whilst under the acute effects of ketamine: “And I thought,
hang on, what have I let myself in for you know?What is this thing?
What the hell is going on here?” (P08).
These thoughts and feelings of paranoia were described to be
“strong” and “overwhelming.” Additionally, these thoughts were
linked with beliefs that they would be stuck in this situation for
the rest of their lives:
“I can remember thinking, feeling very paranoid that the whole trial
was kind of a fake and it was like trying to get me into this situation.
And that I was actually going to be in a situation for the rest of my
life” (P04).
The transient physically distressing experiences took the form of
paralysis and nausea and vomiting. A few participants described
feeling nauseous and sick during the infusions. A number of
participants reported varying degrees of paralysis, whereby they
were not able to move parts of their body due to feelings
of detachment:
“And it’s almost like a state of paralysis, where you do receive visual
and sound information. But I don’t know how much sense I was
making to the people in the room around me. It feels like when you
try and run in a dream, but your legs aren’t moving fast enough. In
fact, exactly like that” (P08).
Another set of contradictory experiences involved on one
hand experiences of dissociation, detachment, floating,
otherworldliness and on the other hand ego dissolution
characterised by feelings of connectedness with other beings,
decreased self-importance, a sense of the small self-fitting in with
the vastness of the universe.
Dissociation, Detachment, or Floating
Nearly all participants reported feelings of dissociation or
detachment, either from their environment, their physical body,
or their sense of self: “I kind of lost a sense of who I was. I
couldn’t—there didn’t seem to be no connection with normality
and what, how I usually felt” (P04).
Other experiences of dissociation involved participants feeling
detached from their physical bodies or feeling as though their
bodies had disappeared: “. . . My whole feeling of my body
disappeared. . . . It was like being an amoeba and just floating
in space. I had nobody, I had no- I was a soul” (P03). For
some people this experience of was accompanied by feeling of
paralysis, which was reported as disturbing, as intense feelings of
detachment made them feel like they had no physical connection
to their bodies: “One further thing I remember is I couldn’t actually
move any part of my body because of the detachment.” (P04).
In an extreme case of detachment from their physical body,
one participant reported what they described as a near death
experience: “I was this entity of pure whiteness, and I was above
myself.... As far as I was concerned, that was it. I could be dead.
I could have been that was it. I could have stayed white forever.”
(P05).
Otherwordly Experiences
Participants also reported experiences which can be described as
dissociation from the world; ketamine infusions were commonly
described as “out of this world,” “otherworldly” or opening one
up to a “new realm”: “That infusion took me somewhere that was
outworldly, was out of this world. It was not within this world”
(P05).
Ego Dissolution
In direct contrast to these experiences of dissociation or
detachment from one’s sense of self, physical body or the world
around them, experiences of ego dissolution were reported; these
were characterised by a diminishing sense of self as distinct
from other beings and feelings of unity with the rest of the
universe. Some of these experiences were primarily characterised
by decreased absorption by one’s own issues and concerns and a
decrease in sense of self-importance:
“I felt a sense of all the things that I decide or wanted or had
or didn’t have, was kind of understandable in a sort of childish
way but actually not what was important... I didn’t have any
acquisition, or requirements or needs. I was over that. It was a sense
of completeness, a sense of, I suppose finality, a source of finish”
(P07).
Whilst for others, this experience of decreased self-importance
and decreased self-absorption was linked to a feeling of
connectedness with other beings, a sense of the “small self ”
and/or fitting in within the vastness of the universe:
“It was almost like the universe was surrounding me and I was just
the most tiny you know, small, small and fundamental particle,
you know. From this feeling of like this huge vastness and me being
absolutely nothing or very, very, extremely small. And because of
that tininess of me, it was almost like all the things that made me no
longer existed” (P04).
Rapidly Fluctuating and Changing Experiences
Perceptual Distortions
All participants reported perceptual distortions, which were
variable in nature and changed throughout the experience.
These took the form of visual and auditory distortions and
hallucinations or visions. Visual distortions weremost commonly
reported, which included dimensional and spatial distortions,
whereby objects and people felt smaller or larger, closer, or further
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away, or had a different shape or texture: “I could feel different
textures of surfaces. I could see movement of these surfaces like
snakeskin scales or lava. And different shades of colours” (P07).
For some, this involved feeling themselves as smaller or larger
in comparison to the room. “I got a sort of spatial sense of
being enormous or being tiny.” (P07). Aspects of texture and
colour were also altered for these participants. Most participants
reported changes in colour perception, which was described as
“beautiful” and an “explosion of colour.”
Others reported auditory distortions, such as voices sounding
further away or closer and musical pieces being unrecognisable
“It’s like different aspects that made up the piece were coming
through at different speeds or different pitches. . . . I could still
hear them as piano pieces but they weren’t the pieces that I knew”
(P04); or changing depending on their concurrent psychoactive
experience: “So, when the music tempo picked up, it’s sort of
moved into a different place within the journey that you were on
essentially” (P11).
These experiences of visual and auditory distortions were
reported to change and evolve throughout the infusion, this is
key to the rollercoaster of experiences whereby perceptions and
reality are rapidly changing:
“Sometimes it would become very linear, everything will be at right
angles and lines and squares. And other times it would be just like
a blur it would just be colours. And it would constantly change
and evolve, what I was seeing would evolve and what I was hearing
would evolve as well” (P04).
On the other hand, for some the sensory changes were more
extensive than simple distortions, crossing over into what can
be described as hallucinations or visions. These were very
subjective, ranging from research staff transforming into Alice
in Wonderland characters, images of being surrounded by
hundreds of people, images of being surrounded by pink
blancmange and abstract hallucinations of a biological nature:
“So, everybody turned into Alice in theWonderland for me. . . . And
then the other one I can’t remember her name, she is wonderful,
but she was the Cheshire cat. So, when she walked in, she had this
massive grin” (P05).
Meaningful, Spiritual, and Mystical Experiences
Ego Dissolution, Epiphanies, and Enlightenment
For several participants, these experiences of ego dissolution
during the ketamine infusions were connected to gaining deep
andmeaningful insights to important aspects of their life (see also
theme 4 below). For some, this took the form of gaining insights
into a sense of what was important in life:
“It was about material things, not wanting those, those aren’t really
important. And neither is the sense of doubt and self-criticism, you
know, it’s almost like life’s too short. In a way, I felt like life was
over. I can let these things go; you know that they are not really that
important. Almost like simplistically, don’t sweat the small stuff ”
(P07).
For one participant the epiphanies involved reflections on life
and death:
“. . . Life and death is not a black and white thing. It’s not a switch
on and switch off when you die. They are a passage and I’m a part
of it here and I’m a part of it whenever that other thing happens”
(P06).
Another participant experienced an epiphany about many
aspects of their life including an understanding about the need
to integrate traumatic experiences within oneself; as we explore
in the next theme, for this participant, these new understandings
led to significant transformations in their life:
“So, if trauma was like a ball so like you’ve got something about the
size of a tennis ball that has a trauma experience. It’s attached to
your body. You canmove it around in the body, but it’s still attached
to you. It’s unpicking that fabric and weaving the fabric into your
being. So, it doesn’t cease to exist, but its power is gone” (P09).
Transcendence of Time
Some participants reported experiences where a sense of time
as we know it was eliminated. For some, distortions of time
produced the fear of the experience lasting for eternity. For
others, distortions of time had a more profound effect and put
into perspective the normal ordering of events in society: “Now,
this afternoon, this evening, the way we think of that—That just
blows apart and doesn’t exist anymore” (P06).
Hallucinations or Visions
For some, hallucinations and visions were related to religious,
spiritual, and mystical experiences:
“. . . .we are all connected and there is this connection between all
beings, people and things to again bring us out of this kind of prison
of addiction. The transpersonal effects of the drug bring us out of
ourselves and put the problems into perspective” (P09).
For one participant this took the form of encountering and
talking to God. He described these experiences as “holy” and
these visions were closely related to epiphanies:
“And so essentially, it was like this higher power, this representation
of the higher power [referring to God] that had appeared at the start
was showing that I had permission to be happy and do I what want,
as long as I didn’t misuse my resources” (P09).
It is important to note that every participant reported these
acute ketamine effects as being transient in nature, with the only
psychoactive effects in the following few hours being mild, such
as “strange” feelings, slight feelings of confusion, or mild visual
effects whilst going to sleep. Many participants reported that
ketamine infusions had positive effects on their mood in the days
following the infusions. These included reports of feeling “chilled
out,” at peace, reflective, happy, energetic, or just generally being
in a better mood but for most these positive effects on mood were
brief and returned to baseline within a week.
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The Ketamine Infusions and the Trial as Potentially
Transformational
Perspective on Life
The combination of the ketamine infusions and the trial as a
whole were reported to be transformational in many aspects
of participants’ lives: “In a non-cheesy way, it actually probably
changed my life around and kept me alive” (P12). The effects of
the trial were described as helping “every single avenue” of one’s
life (P03), as well as a “real fundamental shift in gears” (P09).
It’s important to note that not all participants reported these
transformational effects of the trial, several participants expressed
that the trial did not lead to a fundamental lasting change on their
perspective of life. Though one of these participants described the
trial as a “major a part of a process” which allowed them to move
forward with regards to their mental health.
Relationship With Alcohol
Whilst only three participants were still completely abstinent
at the time of interview, all participants who completed
the treatment recounted that the trial had transformed their
relationship with alcohol in a number of ways. For some, this
consisted of a switch from uncontrolled to a more controlled
drinking approach, whereby participants were able to remain
abstinent for much longer periods and consume much less
alcohol: “I still drink, but I’m quite capable of having 2, 3, 4, 5, 6, 7
days where I’m just not bothered about it, which is not something
that happened in the past” (P04).
For others, the transformational effects involved reduced
craving or urge to drink alcohol, which was accompanied by
reduced pleasure from alcohol in some: “I feel I have much less
desire to drink now than I used to. And I think what it is, I actually,
I think, enjoy it less now” (P11).
In some cases, the trial and the infusions resulted in changes in
drinking motives from drinking to cope with negative emotions
or boredom, to drinking for social reasons instead: “It’s more just
sociable drinking now, not: ‘Oh I’ve got nothing to do after I finish
work, I might as well just go get a bottle of rum and drink that”’
(P12).
For participants who were abstinent from alcohol at the
time of interview, the trial led to more fundamental changes in
their relationship with alcohol, where alcohol no longer was the
primary focus of their life which meant that they were able to
prioritise other aspects of their life: “Whilst I was drinking, drink
was the most important thing and drink was the dangerous thing.
It was you know, my love and my hate, drink was and now I’ve
got swimming” (P03). This also involved a switch from wanting
to find a reason not to drink, to longer needing a reason not to
drink: “Right now I’ve got to have a reason. Show me the reason
to drink. I don’t have a reason, I don’t need a reason not to drink
anymore” (P05).
For those who were abstinent from alcohol, some of these
transformational effects were closely linked with the deeply
meaningful, personally relevant, religious, spiritual and mystical
experiences, and dissociative effects during the acute ketamine
experiences. For one participant, overcoming the near death
like experience of extreme dissociation from their physical body
became a coping mechanism for dealing with other problems
in life:
“So moving onwards in life, every time I get something that’s quite
testing or you know a problem, I just say, ‘well, a couple of months
ago, I was just white. . . . So how bad can this be?’” . . . At least I’m
not white, you know, at least I’ve got a body, at least I’m alive kind
of thing (P05).
Similarly, for another participant, the experience of
disembodiment during their first infusion was connected
to their abstinence from alcohol: “. . . After the first one, I
knew I wasn’t going to drink again.” (P03). Indirectly, this
strong experience of dissociation appeared to be related to the
participant forgetting the taste of their drink of choice and thus
desire to remain abstinent: “I don’t recall what pint tastes like,
now a pint was my drink. And I couldn’t imagine the taste, so
instantly I was not wanting to drink” (P03).
For another participant, it was the reduction in self-absorption
and feelings of connection with the universe that seemed to affect
their relationship with alcohol:
“. . . The sense of oneness that I felt and the sense of moving away
from focusing on the worries and the small stuff is helpful in
terms of improving my relationship with alcohol. Because I think
I used alcohol as a self-medication and as a blocking and avoiding
mechanism. And I think feeling that those issues are less prevalent
or at least less important means I feel less motivated to drink” (P07).
A number of participants who reported experiences of ego
dissolution or epiphanies during the ketamine infusions were
not completely abstinent from alcohol at the time of interview.
Whilst they all reported changes in their relationship with
alcohol as explained above, it is not clear whether these
were due to their experiences of ketamine infusions or the
education/psychotherapy: “My attitude towards alcohol has
changed, but I couldn’t say how much that was down to infusions
or education or a combination of the two” (P04).
Positive Experiences of Psychotherapy and Alcohol Education
Another potentially transformative aspect of the trial was
the psychotherapy/psychoeducation sessions provided alongside
ketamine infusions. These were described as “illuminating” and
“engaging.” Participants reported that even if they were vaguely
aware of the dangers of alcohol, through the psychoeducation
sessions they gained an in depth understanding about the
detrimental effects of alcohol on the body and the mind.
In some cases, this knowledge appeared to be linked to the
transformations in drinking behaviour/attitudes to alcohol: “. . .
Actually learning the dangers of over drinking to go: ‘you know
what, I don’t really want to be around it that much anymore”’
(P12).
Only four of the participants interviewed had received the
psychotherapy as part of the trial, nonetheless these participants
recounted the transformational effects of psychotherapy,
including opening one up to different kinds of therapy, as a
support system that kept them focused on their journey, and as
having significant impact on their personality:
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“. . .My persona was a jacket that I could take off and hang up at
the door and do the work. And then put that jacket back on. But the
jacket would be a slightly different colour and then by the end of the
process, it was a different jacket” (P09).
Interaction of Ketamine With Psychotherapy or Education
One possible transformational effect of ketamine infusions
was making participants more receptive, more willing
to engage with and more open minded towards the
psychotherapy/psychoeducation sessions:
“If I had just gone to education sessions and gone: ‘oh well I work
around alcohol all day, I am pretty sure I know all the stuff I need
to know about it,’ I probably wouldn’t have listened so deeply. But
the ketamine sort of made me more willing to engage with it” (P12).
Though for others, there was no obvious connection between
their ketamine experiences and openness to learning new
information as part of the talking sessions.
It is important to discuss whether the transformational
effects reported here are due to the ketamine infusions, the
psychoeducation/psychotherapy sessions, or non-specific trial
effects for instance the care and attention that the participants
reported receiving from the trial staff.
Ketamine and Talking Sessions as Mutually Supportive
Several participants described the ketamine and talking
interventions as a package, components of which mutually
supported each other, and attributed the effects of the trial
to both:
“So, I think that as a package, I hit the golden button, didn’t I? . . . .
Not only did I get a life changing and mind-altering experience, but
then the therapist did plug some new thoughts to me that made me
think differently... I feel that it is really important that when you are
split open, you know, in such an intense and life changing way that
you are given new thoughts and you know that someone gives you
something to refill that, so you do change stuff ” (P05).
Nonspecific Trial Effects
Others mentioned that the benefits they experienced may be due
to other factors associated with the trial and highlighted that the
emotional connection with the therapist and desire to do well for
them also played a role:
“I don’t know whether it was the chemicals, the therapy, the keeping
of the notes, the loyalty, the wish to sort of be a good pupil if you like
in relation to the people involved in the course. . . . And I’m not sure
it’s the therapy that one needs. It’s more the sort of holding hands
that one needs, you need somebody who you’ve sort of divulged all
your innermost secrets to. Having done that, it then sort of makes
you think twice about buying that bottle of wine” (P02).
Participants responded positively to the attention and care they
received from the trial staff and their genuine interest in helping
them: “I did feel throughout the KARE trial, that one of the really
positive aspects of the whole thing was the care and interest in me
that I felt from the staff that I met with and engaged with” (P07).
TABLE 3 | A list of recommendations for future trials of ketamine treatment based
on current findings.
1. Preparation
• Include first person accounts of ketamine experience in the preparation
for infusions
• Emphasise that the experience may involve paranoid thoughts and
altered perception of time, though any affects are transient
• Include a debrief at the end of the ketamine infusions to discuss potential
feelings of loss and sadness associated with the end of treatment
• Screen individuals for tendency towards paranoid beliefs
2. Setting
• Clinical and professional setting may be reassuring for ketamine
naïve participants
• Trusting relationships with the trial staff appear to be crucial in providing a
safe setting
3. Measurements
• Include questionnaires measuring a wide range of the psychoactive
effects of ketamine (religious, mystical, spiritual, and dissociative)
including Hood’s Mysticism Scale, Psychotomimetic States Inventory, and
5-Dimensional Altered Consciousness Rating Scale
• Measure motivations and expectations from treatment using measures
such as The Stages of Change Readiness and Treatment Eagerness and
The Alcohol Abstinence Self-Efficacy Scale
• Development of a new measurement capturing the wide range of acute
experiences reported under ketamine infusions: dissociative, religious,
mystical and spiritual, and otherworldly experiences as well as
perceptual distortions
4. Dosing and Administration
• Consider titrating doses up according to individual experiences
• Consider multiple sessions based on individualised need/experiences
• Investigate the optimal number of doses
DISCUSSION
“.. so, it was showing that essentially, we are all connected.
And there’s this connection between all beings, people, and things
to again bring us out of this kind of prison of addiction, the
transpersonal effects of the drug to bring us out of ourselves and
put the problems into perspective” (P09).
“I have to remember this, because this is going to be one of the best
experiences of my life” (P04).
This study set out to explore the subjective experiences of
individuals in a clinical trial of ketamine for the treatment of
alcohol use disorder. Our use of an open-ended, semi-structured
interview allowed us to identify themes which may not have
been apparent from using a standardised questionnaire or clinical
checklist, and in doing so we were able to uncover a number of
previously unreported effects of ketamine. This work has yielded
important insights into the motivations for and experiences of
ketamine treatment which may be useful for tailoring future
treatments and preparing participants for ketamine treatment
(see Table 3).
Consistent with previous work with psychedelics (23, 24),
but rarely considered in ketamine studies, set and setting
were found to be important in the acute experience following
ketamine administration.Most of the respondents reported being
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comforted by the professional and clinical setting in which the
trial took place. The setting of this trial represents a contrast
with the way the therapeutic environment has been manipulated
in studies of classic psychedelic drugs to feel comfortable and
incorporate natural features (24–26). Whilst it was previously
thought that clinical or medical environments may induce
anxiety or unpleasant experiences (2, 25, 27), this did not reflect
the experiences of the participants interviewed here.
The mindset or “set” was also found to be important:
those who had previous experience of non-ordinary states
of consciousness had found these experiences to be useful
preparations. These reports parallel research in the context of
psychedelics, which showed that readiness to surrender to the
experience and being supported by trusted individuals in a
therapeutic setting protects against challenging psychological
experiences (24). The experiences reported by participants here
further underscore the importance of the context in which
psychedelic drugs such as ketamine are administered. Whilst
previous research investigated the effect of drug by environment
interactions on the acute experiences of psychedelic drugs (28,
29), future research is needed to examine the role of set and
setting in determining the treatment efficacy of psychedelic
drugs (30).
Participants’ reported that ketamine induced religious,
spiritual, and mystical experiences. This may be relevant to the
use of the drug in this group of participants with alcohol use
disorder, as connection to a higher power is a key element in
some approaches to achieving and maintaining sobriety from
alcohol, for example the twelve-step programme. It is possible
that ketamine or other psychedelicsmight once again have a place
alongside these treatment approaches (31) for those who have
struggling to engage with these aspects of these programmes.
Whilst previous research on religious, spiritual, and mystical
experiences (RSME) has dismissed such experiences produced
by psychedelics as artificial compared with spontaneous RSMEs
(32), others argued that the “fruits” (outcomes) of the experience
are more important than its “roots” [cause/origins as William
James cf. (33)] (33, 34). In fact, a previous study has reported that
the RSMEs induced by psychedelic substances were perceived
as more mystical than RSMEs produced through other means
and had greater positive impact on one’s sense of purpose, and
greater increases in individuals’ spirituality (33). The participant
experiences reported here are in line with previous research
demonstrating that psychedelic drugs such as ketamine can
trigger profound RSMEs when administered in highly controlled
and supportive clinical trial settings (25, 30, 35–38). The extent to
which such experiences are related to ketamine’s treatment effects
for addiction remains to be further investigated.
A number of participants reported ego dissolution from
ketamine, which comprised feelings of connectedness with the
universe, and a sense of the “small-self ” fitting in with the
vastness of the universe; similar to experiences commonly
observed with other classic psychedelic drugs such as psilocybin
(1, 30, 38). Whilst feelings of dissociation and detachment that
were reported by the majority of participants are consistent
with previous reports (39, 40) in the current trial these feelings
of detachment from one’s sense of self or one’s physical
body were accompanied by seemingly paradoxical feelings
of connectedness with the universe and of decreased self-
importance and self-absorption.
Acute ketamine experiences reported by patients—feelings
of connectedness, altered time perception, self-diminishment,
perceived vastness, and physical sensations—all map on to
the experience of “awe” which is an increasingly researched
psychological construct (41). Awe has been proposed as
a potential mechanism of action underlying the effects of
classic psychedelic-assisted psychotherapy (42) and theoretically
overlaps with mystical experiences (43), the small self and
ego dissolution (44) and challenging experiences (45) under
psychedelics. The ketamine induced profound sense of awe,
wonder and connectedness may be of particular use in this group
of patients, in helping individuals break the cycle of compulsive
patterns of thinking that are a feature of alcohol use disorders.
Given the reported experiences here, the term “dissociative
anaesthetic” appears insufficient to characterise the wide range of
acute ketamine experiences captured in this study. In previous
clinical trials of ketamine as a mental health treatment, the
Clinician Administered Dissociative State Scale (CADSS) (46)
was the most commonly used tool to assess the dissociative
effects of ketamine (47). However, concerns were raised that
the CADSS may be inadequate to measure such experiences as
it has only been validated in populations with Post Traumatic
Stress Disorder/ dissociative disorders (46) and it does not appear
to fully capture the phenomenological experiences of ketamine
administration (48). It is important to accurately measure the
subjective experience following ketamine, as there is considerable
research interest in whether the acute psychoactive effects of
ketamine mediate its therapeutic effects. Emerging evidence
suggests the mystical, dissociative and psychotomimetic effects
characterising the ketamine’s acute effects may contribute to
its therapeutic benefits (16, 17, 49) parallel to findings in the
psilocybin research which links mystical experiences to treatment
outcomes (50–52). A recent review suggested this evidence to be
inconclusive for ketamine but concluded that this may be due to
the measurement tools used [for a review see (47)].
Whilst a number of terms have been used to describe
ketamine and similar drugs, including hallucinogen (perceptual
alterations), entheogen (producing mystical like experiences),
psychotomimetic (modelling symptoms of psychosis), all seem
to suffer from the issue of focusing on a single aspect of the
experience at the expense of others (2). The term psychedelics
may also not be preferable due to strong connotations with
Western counterculture of the 1960s (2). Additionally, feelings
of connection, epiphanies and the awe aspect of the experiences
are not reflected in any of the proposed names. It may be that
a new nomenclature for characterising the effects of psychedelic
drugs is needed, whereby each drug might be described in terms
of the extent to which the described categories of experiences
are reported.
Nearly all participants experienced transient periods of
psychological and physical distress during the ketamine
infusions. Despite reports of trusting relationships with the trial
staff, under the effects of ketamine a small of number participants
questioned the veracity of the trial or the motivations of the trial
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team; these strong and overwhelming paranoid thoughts were
linked with beliefs that the experience would never end, which
were reported as being frightening. An important suggestion
emerging from this work therefore is that in preparation sessions
it should be discussed with patients that they may experience
such thoughts and their perception of time might be affected
during the infusions, though any affects are transient. Whilst
individuals with psychosis/schizophrenia and family history of
such disorders were excluded from the trial, it may also be worth
considering specifically screening for individuals with paranoid
beliefs prior to their involvement in a ketamine trial. Crucially,
none of the participants reported prolonged psychosis or lasting
perceptual alterations beyond the acute infusions.
Some participants described each infusion allowing further
insights and understanding, likening the infusions to a three-
part story. This was linked to a desire to have more than
three infusions, to “go a little bit further.” Tachyphylaxis
(rapidly developing tolerance) was described even over these
three sessions which may suggest future doses might need
to be titrated up. Indeed, similar approaches have been used
in Ketamine Assisted Psychotherapy and psilocybin treatment,
whereby following the first dose, subsequent doses were titrated
up according to individual experiences to achieve a “mystical”
(52) or “trance” state (53). Additionally, higher doses were found
to be predictive of a “peak” [based on (54)] or “mystical” (35)
psychedelic experience (28) which has been linked to treatment
efficacy (55) and titrating up is common in the private ketamine
therapeutic practise in the US (56).
All participants interviewed here reported positive
experiences associated with the ketamine infusions overall
despite the transient distressing experiences. This suggests
that short-lived intense distress can be well-tolerated by study
participants in a supportive and therapeutic setting as part
of a clinical trial (38). One of the interviewed participants
reported an isolated incident of recreational ketamine use
following the trial. There are concerns about the abuse
potential of ketamine, but this may suggest that when
provided in a treatment context to participants who were
appropriately screened, supervised, and followed up [see (2)
for safety guidelines in human hallucinogen research] the risks
are minimised.
Whilst only three of 12 participants were abstinent from
alcohol at the time of interview, all participants who completed
the three infusions (N = 11) described lasting changes in their
relationship with alcohol, suggesting a shift from uncontrolled
to a more controlled drinking approach: ability to remain
abstinent for longer periods, reducing amount of consumption,
reduction in craving to drink alcohol and changes in motives for
consuming alcohol. This is a particularly valuable insight from
qualitative data, which would not be possible to ascertain from
the quantitative data on relapse rates alone. Similar findings of
controlled drinking following treatment have also been reported
in the psychedelic literature (52). This may also indicate future
trials may need to consider outcomes beyond abstinence or
relapse rates in evaluating ketamine’s therapeutic effects for
alcohol use disorders. The appropriate outcome measurements
may be related to patients’ motivations and expectations from the
treatment, as well as perceived self-efficacy to remain abstinent,
as these factors are shown to be strongly related to long term
drinking outcomes (57).
There are a number of limitations to consider in the current
study. Firstly, the interviews were conducted on average 2 years
following participants’ involvement with the KARE trial and the
ketamine infusions, therefore their memory of their experiences
may be subject to distortion. The acute and long-term benefits of
ketamine reported by the participants here may also be explained
as a result of other non-specific factors associated with taking
part in a clinical trial including the rapport with the therapist,
the care and attention received during the trial and wishing to
please the trial team as reflected by a number of participants here
[e.g., (30)]. Participants may have also felt a wish to report more
positive experiences of the infusions or the trial to please the
interviewers, however the fact that researchers undertaking the
interviews were not previously known to the participants may
have minimised this.
The current study reported patient perspectives of ketamine
treatment in the context of a clinical trial for alcohol
use disorders. The experiences reported here highlight the
importance of supportive, safe, and a professional environment
in determining individuals’ acute ketamine experiences. For
majority of the participants, the acute ketamine experience
included dissociative effects, transient distress and perceptual
distortions; though some also reported more profound religious,
spiritual, and mystical experiences such as ego dissolution and
epiphanies. Whilst some of these experiences including strong
feelings of dissociation as well as feelings of connectedness,
appeared to be related to the transformations reported by
the participants, the extent to which these acute experiences
contribute to ketamine’s therapeutic effects for alcohol and/or
substance use disorders remains to be fully investigated. The
wide range of acute experiences reported here are not captured
by ketamine’s characterisation as a “dissociative anaesthetic.”
Keeping this in mind along with issues highlighted with other
terminology, a new nomenclature for describing the effects
of ketamine and other “psychedelic” drugs, as well as the
development of a new measure to appropriately assess ketamine’s
acute effects are recommended. Beyond the acute effects,
potentially transformative effects of ketamine infusions and the
trial are reported. For some participants, insights from the acute
ketamine experience have had significant positive effects on
many aspects of their lives. For the majority, the treatment is
reported to have led to significant change in their relationship
with alcohol. How ketamine interacts with psychotherapy, as well
as the most appropriate psychotherapy to be delivered alongside
ketamine treatment remains to be determined; qualitative
analyses such as these are vitally important in informing
such approaches.
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APPENDIX
SECTION 1: ACUTE EXPERIENCES OF THE
KETAMINE INFUSION
1. Circumstances around deciding to participate: Thinking back
to the time period prior to starting the trial, what was it that
made you consider taking part?
2. Experiences during ketamine infusion: Thinking back to when
you were taking part in the trial, could you describe your
experiences whilst being given the infusion? (Prompts—liked
and disliked aspects).
a. Was the experience similar each time you were given a
ketamine infusion?
b. Any more positive or negative experiences you’d like
to report?
3. Long-term experiences: Could you now please describe your
experiences in the week following the infusion?
a. Prompts: did you find that the effects of the ketamine had
any lasting effects after the duration of the infusion?
b. E.g., immediately after infusion, in the days following
infusion, in the weeks following infusion.
4. Effects on world/alcohol perspective: Do you think that the trial
changed the way you see the world in any way?
a. Has anything changed around your relationship
with alcohol?
b. Has anything changed with your mood?
5. Interaction with therapy: What were your experiences
participating in the talking session [therapy/psychoeducation]
following the ketamine infusion?
a. Thinking about whether the ketamine helped or did not
help your engagement with the talking session
SECTION 2: RUMINATIVE
THINKING STYLES
In the next section, we’d like to ask you some questions about
your thinking patterns, particularly about a thinking style called
rumination. Have you heard of this term before? Could you tell
me what your understanding of rumination is?
Rumination is a repetitive, negative, and self-critical thinking
pattern about one’s self, feelings, personal concerns and upsetting
experiences. It is often difficult to control this thinking pattern once
it starts.
6. Topics of rumination: Typically, people ruminate
about a great number of things. I wonder if you
could tell me about some of the main things that
you tend to ruminate about and your general
experience of ruminating.
7. Triggers of rumination: Thinking about when you have these
repetitive thoughts, what starts it off?
a. Prompts: negative mood, upsetting experiences?
8. What ends the rumination: Is there anything that tends to
end/stop these thoughts?
9. Effects of rumination on mood: Thinking about when you’re
ruminating, do you notice any change in yourmood or craving
for alcohol?
10. Changes in rumination: Have you experienced any changes
in your ruminative thinking following the treatment? (specify
timeline: following the treatment you received during
the trial).
a. Prompts: Change in how often you tend to ruminate,
b. Whether you find it easier to control
ruminative thoughts
c. Change in what starts and ends rumination.
Final section involves some questions about your current alcohol
and drug use.
SECTION 3: CURRENT ALCOHOL AND
DRUG USE (YES/NO)
11. Have you been using alcohol since you finished participating
in the trial?
a. If yes, when did you start? What do you attribute this to?
b. How frequently? (Days in month)
c. Last 14 days of alcohol use
12. Have you at used ketamine or any other drugs recreationally
since finishing participation in the trial?
a. Which drugs?
b. How frequently (days in a month) what dose in a session?
(A session is each occasion of use)
DEBRIEF
Is there anything else you would like to report related to your
experience taking part in the KARE trial?
Do you have any questions?
Frontiers in Psychiatry | www.frontiersin.org 17 August 2021 | Volume 12 | Article 695335
